KMT2A and leukemia: To confirm that the DOT1L inhibitors used were active, we analyzed a known DOT1L-dependent MLL-rearranged leukemia cell line (MV4-11) and a known DOT1L inhibitor insensitive T-cell leukemia cell line (Jurkat) (Daigle et al., 2013).